Phio Pharmaceuticals Announces "How siRNA Therapy can Change the Course of Cancer Treatment" in a Fireside Chat with Force Family Office on Monday, June 29, 2026
Rhea-AI Summary
Phio Pharmaceuticals (NASDAQ: PHIO) will join a live virtual fireside chat hosted by Force Family Office on Monday, June 29, 2026 at 12 PM EDT. CEO Robert Bitterman and Dr. James Cardia will discuss siRNA therapy, skin cancer treatments, and Phio’s INTASYL® immuno-oncology program.
Positive
- None.
Negative
- None.
News Market Reaction – PHIO
On the day this news was published, PHIO declined 5.90%, reflecting a notable negative market reaction. This price movement removed approximately $743K from the company's valuation, bringing the market cap to $11.85M at that time.
Data tracked by StockTitan Argus on the day of publication.
Key Figures
Historical Context
| Date | Event | Sentiment | 24h Move | Catalyst |
|---|---|---|---|---|
| Jun 24 | Pipeline milestone | Positive | -1.9% | Commercial-scale cGMP production of PH-762 to support next clinical phase. |
| Jun 18 | Investor conference | Positive | -2.3% | Participation in Life Sciences Investor Forum to present INTASYL and PH-762. |
| May 26 | Non-deal roadshow | Positive | -0.9% | Virtual non-deal roadshow highlighting INTASYL platform and PH-762 trial. |
| May 12 | Fireside chat | Positive | +1.9% | Fireside chat discussing PH-762 Phase 1b data and operational runway. |
| May 07 | Earnings & update | Neutral | -6.1% | Q1 2026 financials and PH-762 development update with higher R&D spend. |
24h Move is the share-price change in the day after each event; other market factors may also have contributed.
PHIO often trades weakly after generally positive operational or outreach news, with more divergence than alignment in recent events.
Key Terms
sirna medical
gene silencing medical
immuno-oncology medical
AI-generated analysis. How Rhea-AI works. Not financial advice.
Live virtual fireside chat - investors, advisors, and life sciences analysts invited to attend
King of Prussia, Pennsylvania--(Newsfile Corp. - June 25, 2026) - Phio Pharmaceuticals Corp. (NASDAQ: PHIO) is a clinical-stage siRNA biopharmaceutical company developing therapeutics using its proprietary INTASYL® gene silencing technology to eliminate cancer. Phio announced today that Mr. Robert Bitterman, CEO and Chairman of the Board, Phio Pharmaceuticals will participate in a fireside chat with Harvey Briggs, Chief Communications Officer, Force Family Office. Joining them will be James Cardia, Ph.D., who will explore siRNA therapy and skin cancer treatments.
"We are excited to take part in this fireside chat with Force Family Office," said Robert Bitterman, CEO and Chairman of Phio Pharmaceuticals. "Dr. Jim Cardia will discuss the future direction of siRNA oncology and highlight how our INTASYL® siRNA program represents a differentiated and innovative approach to immuno-oncology."
DATE: Monday June 29, 2026
TIME: 12 PM EDT
REGISTRATION LINK: PHIO Pharma - Force Family Office
About Phio Pharmaceuticals Corp.
Phio Pharmaceuticals Corp. (NASDAQ: PHIO) is a clinical-stage biopharmaceutical company advancing its proprietary INTASYL® siRNA gene silencing technology to eliminate cancer. Phio's INTASYL compounds are designed to enhance the body's immune cells to more effectively kill cancer cells. Phio's lead clinical development program is an INTASYL compound, PH-762, that silences the PD-1 gene implicated in various forms of skin cancer. The Phase 1b trial (NCT# 06014086) evaluated PH-762 for the treatment of cutaneous squamous cell carcinoma, melanoma and Merkel cell carcinoma. PH-762 is a potential non-surgical treatment for skin cancers.
For additional information, visit the Company's website, www.phiopharma.com.
Forward-Looking Statements
This press release contains forward-looking statements within the meaning of the Private Securities Litigation Reform Act of 1995. Forward-looking statements can be identified by words such as "intends," "believes," "anticipates," "indicates," "plans," "expects," "suggests," "may," "would," "should," "potential," "designed to," "will," "ongoing," "estimate," "forecast," "target," "predict," "could" and similar references, although not all forward-looking statements contain these words. These statements, which include statements, among other things, regarding the anticipated benefits of our INTASYL™ RNAi platform, the results from our ongoing clinical trials, our expectations that our cash runway will extend into the first half of 2027, our expectations regarding timing of FDA submissions intended to propose and seek guidance for next steps in clinical study design for PH-762, our expectations that such FDA submissions and any related FDA meetings will clarify next steps in advancing the PH-762 development program, details regarding our planned non-clinical toxicology study, and our ability to support ongoing clinical development, operational requirements and strategic initiatives with the capital we currently have on hand, are based only on our current beliefs, expectations and assumptions and are subject to inherent uncertainties, risks and changes in circumstances that are difficult to predict and many of which are outside of our control. Our actual results may differ materially from those indicated in the forward-looking statements as a result of a number of important factors, including, but not limited to, the impact of future FDA interactions on the development of our product candidates; the impact to our business and operations by inflationary pressures; recession fears; the development of our product candidates, results from our nonclinical, preclinical and clinical activities, our ability to execute on business strategies, our ability to develop our product candidates with collaboration partners, and the success of any such collaborations, the timeline and duration for advancing our product candidates into clinical development, the timing or likelihood of regulatory filings and approvals, the success of our efforts to commercialize our product candidates if approved, our ability to manufacture and supply our product candidates for clinical activities, and for commercial use if approved, the scope of protection we are able to establish and maintain for intellectual property rights covering our technology platform, our ability to obtain future financing, market and other conditions and those risks identified in our most recent Annual Report on Form 10-K and subsequent Quarterly Reports on Form 10-Q under the caption "Risk Factors" and in other filings the Company periodically makes with the U.S. Securities and Exchange Commission. Readers are urged to review these risk factors and to not act in reliance on any forward-looking statements, as actual results may differ from those contemplated by our forward-looking statements. Phio does not undertake to update forward-looking statements to reflect a change in its views, events or circumstances that occur after the date of this release, except as required by law.
Contact:
Phio Pharmaceuticals Corp.
Jennifer Phillips: jphillips@phiopharma.com
Corporate Affairs
To view the source version of this press release, please visit https://www.newsfilecorp.com/release/302679